Drug Trial Radar · NCT03780179
MMR at 6 Months Trial
Last checked: Nov 20, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,540
Actual
Start
Apr 15, 2019
Primary completion
Jan 7, 2022
Study completion Jan 7, 2022
Sponsor
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 months, up to 7 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomised, double-blind clinical trial to test humoral and cellular immunogenicity, and potential in-direct beneficial effect of the MMRvaxpro-vaccine administered at 6 months of age
Conditions
- Meales-mumps-rubella Vaccine
Interventions
MMRvaxproBiological
MMRvaxpro vaccine
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Humoral immunogenicityTime frame: 1 months after intervention
- Hospitalisation for infectionTime frame: 6-12 months of age
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Herlev Hospital
Herlev, Denmark
Rigshospitalet
Copenhagen, Copenhagen Ø, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.